A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

NCT07181694 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

444

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Male

Interventions

DRUG: Adalimumab (BCD-057) 100 mg/mL
DRUG: Adalimumab (BCD-057) 50 mg/mL
DRUG: Adalimumab (Humira) 100 mg/mL

Sponsor

Biocad